Abstract 959P
Background
The efficacy of immune checkpoint inhibitors combined with antivascular agents has been demonstrated in a variety of solid tumors including HCC. Suvemcitug, selectively binds to and blocks VEGFA from binding to VEGFR1 and 2, thereby inhibiting its activities and preventing tumour angiogenesis and ultimately suppressing tumour growth and metastasis. Envafolimab is a humanized single-domain anti- PD-L1 antibody which is administered subcutaneously (SC). This study aims to assess the efficacy and safety of the combination of suvemcitug and envafolimab as second-line or later therapy in patients (pts) with advanced HCC.
Methods
This was an open-label, multi-cohort, multicenter, phase II trial conducted in China. In Cohort B, eligible pts had received at least one prior line of treatment for HCC and were treated with suvemcitug (2 mg/kg IV Q3W) plus envafolimab (300 mg SC Q3W) until disease progression or unacceptable toxicity was observed. The primary endpoint was objective response rate (ORR) assessed by investigator review using RECIST v1.1. Secondary endpoints included disease control rate (DCR), duration of overall response (DoR), progression-free survival (PFS) and safety.
Results
As of March 31,2023, a total of 20 patients were treated with envafolimab and suvemcitug. 80.0% pts (16/20) received one prior therapy and 40.0% pts (8/20) were prior treated with immunotherapy. After a median follow up of 7.4 (5.0, 9.3) months, in 18 efficacy-evaluable patients, the confirmed ORR was 11.1% (2/18), and the DCR was 72.2% (13/18). The median PFS was 4.3 (95% CI 1.4-8.1) months. The most common grade 3 or greater treatment-related adverse events were proteinuria (20.0%,4/20), hypertension (5%,1/20), platelet count decreased (5%, 1/20), blood bilirubin increased (5%, 1/20), γ-glutamyl transferase increased, oesophagitis (5%, 1/20),and oral ulcer (5%, 1/20). No treatment-related death was reported.
Conclusions
The use of envafolimab and suvemcitug did not result in increased safety concerns. Suvemcitug and envafolimab demonstrated antitumor activity and manageable safety profile in pts with prior treated HCC. Research Sponsor: Shanghai Xianxiang Medical Technology Co., Ltd. and 3D Medicines Inc.
Clinical trial identification
NCT05148195.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Xianxiang Medical Technology Co., Ltd. and 3D Medicines Inc.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18